Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry (Q37205563)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 February 2009

Language	Label	Description	Also known as
English	Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry	scientific article published on 19 February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

inflammatory breast cancer

1 reference

based on heuristic

inferred from title

Hoda Anton-Culver

5

object named as

Hoda Anton-Culver

1 reference

Europe PubMed Central

18 August 2017

author name string

Jason A Zell

1

1 reference

Europe PubMed Central

18 August 2017

Walter Y Tsang

2

1 reference

Europe PubMed Central

18 August 2017

Thomas H Taylor

3

1 reference

Europe PubMed Central

18 August 2017

Rita S Mehta

4

1 reference

Europe PubMed Central

18 August 2017

publication date

19 February 2009

1 reference

Europe PubMed Central

18 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

18 August 2017

11

1 reference

Europe PubMed Central

18 August 2017

R9

1 reference

Europe PubMed Central

18 August 2017

1

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1186/bcr2225

0 references

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Prognostic significance of HER-2 status in women with inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Inflammatory breast cancers in Tunisia and France show similar immunophenotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Clinical aspects of inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Short- and long-term cause-specific survival of patients with inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

14 September 2017

WISP3 is a novel tumor suppressor gene of inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

28 September 2017

Trastuzumab in inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

26 June 2018

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

26 June 2018

Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

High incidence of HER-2 positivity in inflammatory breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Socioeconomic status and breast cancer incidence in California for different race/ethnic groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Breast cancer in Tunisia: clinical and epidemiological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR2225

21 January 2018

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends for Inflammatory Breast Cancer: Is Survival Improving?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR2225

1 reference

Europe PubMed Central

18 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37205563&oldid=2145882506"